Valeant gets additional notices of default from bondholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/15/2026
- Dow hits record high on US-Iran deal optimism, oil prices slide
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- This stock is the biggest winner from higher voltages in the Datacenter IT room
- This company's long-term growth remains underappreciated: Wolfe
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
Valeant Pharma (VRX) Appoints Joseph Papa as CEO
April 25, 2016 8:38 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that its Board of Directors has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. Mr. Papa will join Valeant from Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer. Mr. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a... More
Valeant Pharma (VRX) Announces Receipt of Additional Notice of Default Due to Delay of 10-K Filing
April 25, 2016 6:28 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that, as a result of the delay in the Company filing its Form 10-K for the fiscal year ended December 31, 2015 (the "Form 10-K"), it has received notices of default from the trustee under the indentures governing its 5.375% Senior Notes due... More
